Werewolf Therapeutics climbs on FDA's 'fast track' tag for cancer therapy

Werewolf Therapeutics

08/10/2025 13:21

** Shares of drug developer Werewolf Therapeutics HOWL.O rise 20% to $2.32 premarket

** Co says its experimental cancer therapy, WTX-124, got the U.S. FDA's "fast track" designation

** Therapy is aimed at treating advanced skin cancer in patients who have already undergone standard immunotherapy

** FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical need

** WTX-124 is being tested in an early-stage trial as both a standalone treatment and in combination with Merck's MRK.N Keytruda

** As of last close, stock up 30% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))